Cholera toxin chimera and its use as a staph vaccine

ABSTRACT

The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of  Staphylococcus aureus . One embodiment of the present invention provides a method of generating an immune response in a mammal, that includes administering to the mammal, a composition having a chimeric protein having at least one of: a portion of a cholera toxin, a portion of a heat-labile toxin, and a portion of a shiga toxin; and an antigen having at least one of: an antigenic material from  S. aureus  and an antigenic material from a  S. aureus -specific polypeptide.

FEDERAL FUNDING LEGEND

This invention was supported in part with government support under USDACREES Seed Grant #2009-01778, 2008 WWAMI ITHS Small Project Grant #3872and NIH Grant #P20 RR016454 from INBRE Program of the National Centerfor Research Resources. The Government has certain rights in theinvention.

SEQUENCE LISTING

The instant application contains a Sequence Listing which was the onlySequence Listing filed in the parent case U.S. application Ser. No.13/328,686 (now U.S. Pat. No. 8,834,898), filed Jun. 20, 2013. TheSequence Listing was compliant with 37 CFR 1.821-1.825, and is used asthe computer readable form for the present application, in accordancewith 37 CFR 1.821(e).

BACKGROUND

The present invention relates to infectious diseases and, moreparticularly, to chimeric protein vaccines and methods of use thereof inthe treatment of Staphylococcus aureus.

Staphylococcus aureus (S. aureus) is a common cause of hospital-acquiredinfections and represents an important public health threat. S. aureuscan cause nosocomial (hospital) and community-acquired infectionsincluding impetigo, cellulitis, food poisoning, toxic shock syndrome,invasive necrotizing pneumonia, and endocarditis. S. aureus is also themost common species of staphylococci to cause Staph infections.Currently, it is one of the top causes of infectious disease deaths inthe United States.

S. aureus also causes mastitis, which is a major problem in dairy cowswith considerable economic implications. For example, mastitis in dairycows is most commonly caused by S. aureus and is one of the most commondiseases infecting dairy cattle in the United States. S. aureus causes apersistent, inflammatory reaction of the udder tissue that can lead tochronic infections that result in the cow being culled from the herd.Milk from cows with mastitis also typically have higher somatic cellcount, which generally lowers the milk quality. It is estimated thatmastitis may cost the dairy industry billions of dollars per year ineconomic losses.

A growing concern in the treatment of S. aureus is that the bacterium isoften resistant to multiple antibiotics. Roughly half of the nosocomialisolates in the United States are methicillin-resistant S. aureus(MRSA). Methicillin-resistant S. aureus is also sometimes referred to as“multidrug-resistant” S. aureus or “oxacillin-resistant S. aureus.” MRSAbacterium is generally resistant to beta-lactam antibiotics, whichinclude the penicillins (e.g., methicillin, dicloxacillin, nafcillin,oxacillin, etc.) and cephalosporins. Currently, a vaccine that preventsstaphylococcal disease is unavailable.

A possible approach for staphylococcal vaccine development is to targetvirulence factors such as toxins, enzymes, polysaccharide capsules,adhesive factors, and the like. A key to the possible vaccine approachmay be that the anterior nares of humans are known to be an importantniche for S. aureus. It is believed that nasal carriage is a major riskfactor for invasive infection.

One potential S. aureus virulence factor is the iron-regulated surfacedeterminant A (IsdA). IsdA is an S. aureus surface adhesin protein thatmay be immunogenic in certain organisms. IsdA can bind to humandesquamated nasal epithelial cells and is believed to play a criticalrole in nasal colonization.

However, a major obstacle in vaccine development of S. aureus is thelack of immunostimulatory adjuvants that can function from mucosalsurfaces. While certain toxins (e.g., cholera toxin and heat-labiletoxin) have the ability to induce mucosal and systemic immune responsesto co-administered antigens, these bacterial proteins are generally tootoxic for human use.

SUMMARY OF THE INVENTION

The present invention relates to infectious diseases and, moreparticularly, to chimeric protein vaccines and methods of use thereof inthe treatment of Staphylococcus aureus.

In some embodiments, the present invention provides methods ofgenerating an immune response in a mammal comprising: administering tothe mammal a composition comprising: a chimeric protein comprising atleast one of: a portion of a cholera toxin, a portion of a heat-labiletoxin, and a portion of a shiga toxin; and an antigen comprising atleast one of: an antigenic material from S. aureus and an antigenicmaterial from an S. aureus-specific polypeptide.

In other embodiments, the present invention provides methods ofvaccinating a cow comprising: administering to the cow a chimericprotein comprising: an adjuvant selected from the group consisting of: aportion of a cholera toxin, a portion of a heat-labile toxin, a portionof a shiga toxin, and any combination thereof; and an antigen selectedfrom the group consisting of: an antigenic material from S. aureus, anantigenic material from a S. aureus-specific polypeptide, and anycombination thereof.

The features and advantages of the present invention will be readilyapparent to those skilled in the art upon a reading of the descriptionof the preferred embodiments that follows.

BRIEF DESCRIPTION OF THE DRAWINGS

The following figures are included to illustrate certain aspects of thepresent invention, and should not be viewed as exclusive embodiments.The subject matter disclosed is capable of considerable modification,alteration, and equivalents in form and function, as will occur to thoseskilled in the art and having the benefit of this disclosure.

FIGS. 1A-1C show ribbon diagrams illustrating structures of choleratoxin, IsdA, and chimeric protein according to some embodiments.

FIG. 2 shows a diagram illustrating a plasmid that encodes a chimericprotein according to some embodiments.

FIGS. 3A-3B illustrate expression and purification of a chimeric proteinaccording to some embodiments.

FIG. 4 shows a plot showing the results of a receptor binding affinityassay according to some embodiments.

FIGS. 5A-5D show confocal images of chimeric protein binding to Vero andDC2.4 cells stained with fluorescent dyes according to some embodiments.

FIG. 6 shows a plot showing in vivo systemic antibody response tochimeric protein according to some embodiments.

FIG. 7 shows a plot illustrating in vivo mucosal antibody response tochimeric protein according to some embodiments.

FIGS. 8A-8D show plots showing the results of flow cytometry experimentson the proliferation of T lymphocytes from mice immunized with chimericprotein according to some embodiments.

FIG. 9 shows a plot summarizing the flow cytometry results shown inFIGS. 8A-8D according to some embodiments.

FIG. 10 shows a plot showing the results of Resazurin assay ofsplenocytes from mice immunized with chimeric protein according to someembodiments.

FIG. 11 shows a plot showing IL-4 and IN-□ levels of antigen-stimulatedsplenocytes from mice immunized with chimeric protein according to someembodiments.

FIG. 12 shows a plot showing the results of IsdA-specific ELISAtitrations of systemic antibody subtypes according to some embodiments.

FIGS. 13A-13B show a plot showing the effects of immune serum on S.aureus adhesion to human epithelial cells according to some embodiments.

FIG. 14 shows a plot showing milk anti-IsdA IgA titers in cows.

DETAILED DESCRIPTION

The present invention relates to infectious diseases and, moreparticularly, to chimeric protein vaccines and methods of use thereof inthe treatment of Staphylococcus aureus.

There are a number of advantages related to the present invention. Thepresent invention provides compositions (in some embodiments, chimericproteins) that may be useful as vaccines against various strains of S.aureus and related bacteria in various organisms (e.g., mammals such ashumans, cows, etc.).

As used herein, the term “chimeric protein” generally refers to anyprotein comprised of a first amino acid sequence derived from a firstsource, bonded, covalently or non-covalently (e.g., hydrogen bonding,van der Waals force, hydrophobic interaction, etc.), to a second aminoacid sequence derived from a second source, wherein the first and secondsource are not the same. A first source and a second source that are notthe same can include two different biological entities, or two differentproteins from the same biological entity, or a biological entity and anon-biological entity. A chimeric protein can include for example, aprotein derived from at least 2 different biological sources. Abiological source can include any non-synthetically produced nucleicacid or amino acid sequence (e.g., a genomic or cDNA sequence, a plasmidor viral vector, a native virion or a mutant or analog, as furtherdescribed herein, of any of the above). A synthetic source can include aprotein or nucleic acid sequence produced chemically and not by abiological system (e.g., solid phase synthesis of amino acid sequences).A chimeric protein can also include a protein derived from at least 2different synthetic sources or a protein derived from at least onebiological source and at least one synthetic source. For the purposes ofthis disclosure, a chimeric protein may or may not be a singlepolypeptide (i.e., a fusion protein).

In some embodiments, the vaccines may be prophylactic and may beadministered before the onset of S. aureus related infections. It isbelieved that the vaccines of the present invention can activate humoralresponses, stimulate protection, and block the promotion of oraltolerance against S. aureus. Currently, there are no known vaccines thatcan prevent Staphylococcal infection.

The present invention provides compositions that comprise a first aminoacid sequence derived from a suitable adjuvant source and a second aminoacid sequence derived from a suitable antigen source. In someembodiments, the composition may have multiple functions. For example,the first amino acid sequence may act as an adjuvant while the secondamino acid sequence may act as an antigen. As used herein, the term“amino acid sequence” does not necessarily imply a single polypeptide.In other words, the amino acid sequence derived from a suitable adjuvantsource may not necessarily be confined to a single polypeptide. Forexample, a portion of the amino acid sequence may be in one polypeptidewhile the remaining portion of the amino acid sequence may reside inanother polypeptide.

In some embodiments, the composition may be a single polypeptide (e.g.,a fusion protein). In other embodiments, the composition may beassembled from two or more polypeptides. In certain embodiments havingtwo or more polypeptides, one or more polypeptide may be chimeric. Incertain embodiments, the two or more polypeptides may fold or assembletogether within a suitable expression system (e.g., E. coli) or by anyother suitable method (e.g., by the use of chaperone molecules).

The adjuvants typically used to construct the chimeric proteins of thepresent invention may be non-toxigenic or less toxigenic thanfull-length or non-chimeric toxins and yet retain their potent adjuvantcharacteristics. In some embodiments, the adjuvant may have beenmodified from a toxigenic adjuvant source with a modification thatrenders the adjuvant non-toxigenic or less toxigenic and likely suitablefor mucosal surfaces. Such modifications may include, but are notlimited to, mutation of amino acid, removal of toxigenic subunits, andthe like.

As used herein, an “adjuvant” generally refers to a pharmacological oran immunological agent that modifies the effect of other agents (e.g.,drug or vaccine), while having few if any direct effects when given byitself. An immunological adjuvant is often included in vaccines toenhances the recipient's immune response to the antigen, while keepingthe injection of foreign material to a minimum. For the purposes of thisdisclosure, an adjuvant may be linked covalently or non-covalently tothe antigen.

While cholera toxin is an example of a potent adjuvant, it remainsmostly unsuitable for use in humans. Specifically, there are safetyconcerns with the mucosal administration of cholera toxin and othersimilar toxins such as heat-labile toxin and shiga toxin. It is believedthat such administration can redirect antigens to the central nervoussystem through GM1-dependent binding to olfactory epithelium. It hasbeen previously difficult to separate the toxigenicity and adjuvanticityof cholera toxin, heat-labile toxin, and/or shiga toxin.

In some embodiments, the adjuvant source may be a toxin. The adjuvantmay be coupled, assembled, folded, fused, or otherwise associated withan antigen to form a composition that further enhances the immunogeniceffects of the antigen. Examples of suitable toxins include, but are notlimited to, cholera toxin (CT), shiga toxin (ST1, ST2, etc.),heat-labile toxin (LT, LT-IIa, LT-IIb, etc.) from E. coli. In somepreferred embodiments, the toxins are modified to be non-toxigenic whileremaining potent immunostimulatory molecules that can bind to and targetimmune effector cells at mucosal site. It is believed that both shigatoxin and heat-labile toxin are structurally similar or analogous tocholera toxin.

In particular, cholera toxin is a protein secreted by the bacteriumVibrio cholerae and is generally responsible for the massive, waterydiarrhea characteristic of cholera infection. Structurally, choleratoxin is an oligomeric complex made up of six protein subunits: a singlecopy of the A subunit (part A, enzymatic), and five copies of the Bsubunit (part B, receptor binding). The A subunit has two importantsegments: the A1 domain (CTA₁), which is toxigenic and the A2 domain(CTA₂), which forms an extended alpha helix that sits snugly in thecentral pore of the B subunit ring.

FIG. 1A shows a ribbon diagram of the cholera toxin crystal structureshowing the CTA₁ domain (SEQ ID NO: 1) and connecting CTA₂ domain (SEQID NO:2), and the B subunit (SEQ ID NO: 3).

It is believed that cholera toxin immunomodulation may be involved inthe activation of antigen-presenting cells, promotion of B-cell isotypeswitching, and upregulation of costimulatory and major histocompabilitycomplex (MHC) class II expression. Many of these responses result fromthe interaction of the cholera toxin B (CTB) subunit with theganglioside GM1 receptor on effector cells, such as dendritic cells,that promote antigen uptake, presentation, and cellular activation.Thus, suitably modified non-toxigenic forms of cholera toxin by itselfmay act as an antigen carrier and be highly immunostimulatory. Withoutbeing limited by theory, it is believed that heat-labile toxin and shigatoxin are structurally and functionally similar (e.g., adjuvanticity) tothe cholera toxin. For example, heat-labile toxin has an A₁ domain (SEQID NO: 7), A₂ domain (SEQ ID NO: 8), B domain (SEQ ID NO: 9) analogousto the A₁, A₂, and B domains of cholera toxin. An IsdA-LTA₂/B chimericprotein may have a sequence shown in SEQ ID NO: 10.

An antigen is generally any substance that causes the production ofantibodies against it. An antigen may be a foreign substance from theenvironment or it may also be formed within the environment, such asbacterial toxins or tissue cells. Examples of a suitable antigen sourceinclude, but are not limited to, iron-regulated surface determinant A,iron-regulated surface determinant B (IsdB), clumping factor A (ClfA),clumping factor B (ClfB), fibronectin-binding protein (FnBP), penicillinbinding protein 2a (PBP2A), serine-aspartate rich fibrinogensialoprotein binding protein (SrdE), and the like.

In particular, the N-terminal near iron transporter (NEAT) domain ofIsdA is capable of binding to a broad spectrum of human ligands,including transferring heme, fibrinogen, fibronectin, and corneocyteenvelope proteins to mediate adherence and dissemination of S. aureus.The C-terminal domain of IsdA defends S. aureus against human skinbactericidal fatty acids and antimicrobial peptides by making the cellsurface hydrophilic.

FIG. 1B shows a ribbon diagram of IsdA antigen (SEQ ID NO: 4) that isreplacing the toxigenic CTA₁ domain (SEQ ID NO: 1) to construct achimeric protein that comprises an antigen and a non-toxigenic adjuvant.FIG. 1C shows a ribbon diagram of one preferred chimeric protein,IsdA-CTA₂/B (SEQ ID NO: 5).

Some embodiments provide compositions comprising: a chimeric proteincomprising at least one of: a portion of a cholera toxin, a portion of aheat-labile toxin, and a portion of a shiga toxin; and an antigencomprising at least one of: an antigenic material from S. aureus and anantigenic material from a S. aureus-specific polypeptide.

In some embodiments, the composition is a fusion protein. In certainembodiments, the composition is a single polypeptide.

Some embodiments provide a chimeric protein comprising: an adjuvant andan antigen. The adjuvant may be selected from the group consisting of: aportion of a cholera toxin, a portion of a heat-labile toxin, a portionof a shiga toxin, and combinations thereof. The antigen may be selectedfrom the group consisting of: an antigenic material from S. aureus(e.g., carbohydrates, peptides, etc.), an antigenic material from an S.aureus-specific polypeptide, and combinations thereof.

In some embodiments, the adjuvant is one of: CTA₂/B, LTA₂/B, or STA₂/B.In one or more embodiments, the adjuvant further includes at least oneadditional cholera toxin B subunit, heat-labile toxin B subunit, orshiga toxin B subunit. In one or more embodiments, the adjuvant furthercomprises at least one additional cholera toxin A₂ subunit, heat-labiletoxin A₂ subunit, or shiga toxin A₂ subunit.

While some preferred embodiments of the domain and chimeric proteinsequences have been provided, the present invention may be practicedusing any number of alternative embodiments. For example, it is wellknown in the relevant arts that protein or polypeptide variantstypically retain their function as long as they are have sufficientsequence identity with their native sequences.

In some embodiments, the composition has at least about 80% sequenceidentity to SEQ ID NO: 5, 10, or 15. In some preferred embodiments, thecomposition has at least about 90% sequence identity to SEQ ID NO: 5,10, or 15. In certain embodiments, the antigen portion of thecomposition has at least about 80% sequence identity to SEQ ID NO: 4. Insome preferred embodiments, the antigen portion of the composition hasat least about 90% sequence identity to SEQ ID NO: 4. In someembodiments, the composition is assembled from a first polypeptide and asecond polypeptide that are non-covalently linked. In one or more ofthese embodiments, the first polypeptide has at least about 80% sequenceidentity to SEQ ID NO: 6, 11, or 16. In some preferred embodiments, thefirst polypeptide has at least about 90% sequence identity to SEQ ID NO:6, 11, or 16. In some embodiments, the second polypeptide has at leastabout 80% sequence identity to SEQ ID NO: 3, 9, or 14. In some preferredembodiments, the second polypeptide has at least about 80% sequenceidentity to SEQ ID NO: 3, 9, or 14.

Generally, a chimeric protein will be comprised of a single A₂ subunitand a B subunit (from cholera toxin, heat-labile toxin, or shiga toxin).In some optional embodiments, the chimeric protein may further compriseat least one additional B subunit. In some optional embodiments, thechimeric protein may further comprise at least one additional A₂subunit. In some embodiments, the subunits may be linked by a disulfidebond. In some embodiments, the disulfide bond may be engineered. In someembodiments, the antigen has a disulfide bond with the adjuvant. In someembodiments, the antigen is associated non-covalently with the adjuvant.

In some embodiments, the antigen comprises a sequence that has at leastabout 80% sequence identity to iron-regulated surface determinant A,iron-regulated surface determinant B (IsdB), clumping factor A (ClfA),clumping factor B (ClfB), fibronectin-binding protein (FnBP),fibronectin-binding protein (FnBP), penicillin binding protein 2a(PBP2A), or serine-aspartate rich fibrinogen sialoprotein bindingprotein (SrdE). In some preferred embodiments, the sequence identity isat least about 90%.

In some exemplary embodiments, the chimeric protein is IsdA-CTA₂/B (SEQID NO: 5). As used herein, “IsdA-CTA₂/B” generally refers to a chimericprotein that comprises an IsdA antigen domain, a CTA₂ subunit, and a CTBsubunit. In some embodiments, each of the IsdA antigen domain (SEQ IDNO: 4), the CTA₂ domain (SEQ ID NO: 2) and the CTB domain (SEQ ID NO: 3)may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.) ornon-covalently to at least one other domain. In some embodiments, thebond may be an engineered disulfide bond.

In some embodiments, the chimeric protein is IsdA-LTA₂/B (SEQ ID NO:10). As used herein, “IsdA-LTA₂/B” generally refers to a chimericprotein that comprises an IsdA antigen domain, a LTA₂ subunit, and a LTBsubunit. In some embodiments, each of the IsdA antigen domain (SEQ IDNO: 4), the LTA₂ subunit (SEQ ID NO: 8) and the CTB subunit (SEQ ID NO:9) may be bonded covalently (e.g., peptide bonds, disulfide bonds, etc.)or non-covalently to at least one other domain. In some embodiments, thebond may be an engineered disulfide bond.

In some embodiments, the chimeric protein is IsdA-STA₂/B (SEQ ID NO:15). As used herein, “IsdA-STA₂/B” generally refers to a chimericprotein that comprises an IsdA antigen domain, a STA₂ subunit, and a STBsubunit. In some embodiments, each of the IsdA antigen domain (SEQ IDNO: 4), the STA₂ subunit (SEQ ID NO: 13) and the STB subunit (SEQ ID NO:14) may be bonded covalently (e.g., peptide bonds, disulfide bonds,etc.) or non-covalently to at least one other domain. In someembodiments, the bond may be an engineered disulfide bond.

In some embodiments, the chimeric protein may further comprisemodifications that enhance at least one of: solubility of the chimericprotein, specificity for S. aureus, specificity for GM1, expression ofthe chimeric protein, and immunogenicity of the chimeric protein.

Some embodiments provide methods for generating an immune response in amammal comprising: administering to the mammal a composition (e.g.,chimeric protein) according to one or more embodiments described herein.

In some embodiments, the mammal is selected from the group consistingof: a human, a cow, a dog, a cat, and a horse.

In some embodiments, the administration of the composition is byintranasal administration, oral administration, intramuscularadministration, peritoneal administration, sublingual administration,transcutaneous administration, subcutaneous administration, intravaginaladministration, or intrarectal administration. The administered dosageof the composition may generally be an amount suitable to elicit thedesired immune response. In some embodiments, the administering to themammal comprises: administering the composition to at least one cellfrom the mammal in vitro or in vivo.

Some embodiments provide methods for vaccinating a cow comprising:administering to the cow, a chimeric protein according to one or moreembodiments described herein.

To facilitate a better understanding of the present invention, thefollowing examples of preferred embodiments are given. In no way shouldthe following examples be read to limit, or to define, the scope of theinvention.

Example 1

To direct the IsdA-CTA₂ and CTB peptides of the chimera to the E. coliperiplasm for proper assembly, pBA001 (FIG. 2) was constructed frompARLDR19, which utilizes the E. coli LTIIb N-terminal leader sequence.Induction of pBA001 and purification from the periplasm of E. coliresulted in efficient IsdA-CTA₂/B production (3 to 4 mg from 1 liter ofstarting culture). SDS-PAGE analysis of the purification of IsdA-CTA₂/Band immunoblotting using antibodies against CTA and CTB (FIG. 3A)confirm that IsdA-CTA₂ (˜38 kDa) was copurified with CTB (˜11 kDa) onD-galactose agarose, which is indicative of proper chimera folding.Referring to FIG. 3A, the SDS-PAGE analysis shows flowthrough (FT),washes (W1 and W2) and elution (E) of IsdA-CTA₂/B from D-galactoseaffinity purification and anti-CTA/B Western blot of purifiedIsdA-CTA₂/B (˜38 and 11 kDA).

IsdA alone was also purified using a six-histidine tag. FIG. 3B shows anSDS-polyacrylamide gel of all resulting proteins used in animal studies,as well as immunoblotting of purified IsdA with anti-His6 (˜37 kDa):ISdA-CTA₂/B (G1), IsdA plus CTA₂/B mixed (G2), and IsdA (G3).

The following protocol was followed in order to obtain the chimericproteins.

MRSA252 strain was used for IsdA isolation. MRSA USA300 (pvl mutant)strain was used in adhesion assays. E. coli TE1, a □endA derivative ofTX1, and BL21(DE3)/pLysS strains were used for protein expression. Allbacterial strains were cultured using Luria-Bertani (LB) agar or brothat 37° C. with chloramphenicol (35 □g/ml), ampicillin (100 □g/m), and/orkanamycin (50 □g/m).

To construct pBA001 plasmid (FIG. 2) for the expression of IsdA-CTA₂/B,IsdA was PCR amplified from MRSA252 with primers that add 5′ SphIGCTACTGGCATGCGGCAACAGAAGCTACGAAC (SEQ ID NO: 17) and 3′ ClaIGTGCATGATCGATTTTGGTAATTCTTTAGC (SEQ ID NO: 18) sites (in boldface) andcloned into pARLDR19 between the LTIIb leader sequence and CTXA₂. CTBwas also expressed from this vector. To make His6-IsdA, IsdA wasamplified from MRSA252 with primers that add 5′ BamHIGCTACTGGATCCGCGGCAACAGAAGCTACGAAC (SEQ ID NO: 19) orGTGCATAAGCTTTCAAGTTTTTGGTAATTCTTTAGC (SEQ ID NO: 20) and 3′ HindIIIGTGCATGATCGATTTTGGTAATTCTTTAGC (SEQ ID NO: 21) sites (in boldface) andcloned into pTrcHisA (Invitrogen, Carlsbad, Calif.) or pET-40b+,yielding pBA009A and pBA015. pARLDR19 was used to express CTA₂/B for themixed preparation. Plasmids were transformed into E. coli TE1 (pBA001,pBA009A, and pARLDR19) or BL21(DE3)/pLysS (pBA015) and sequenced.

To express IsdA-CTA₂/B and CTA₂/B, cultures with pBA001 or pARLDR19 weregrown to an optical density at 600 nm (OD600) of 0.9 and induced for 15h with 0.2% L-arabinose. Proteins were purified from the periplasmicextract using immobilized D-galactose. For mock cultures, E. coli TE1without plasmid was induced, and the periplasmic extract was purified.IsdA was isolated from the cytosol of cultures containing pBA009A andpurified by cobalt affinity chromatography under denaturing conditions.IsdA was also purified from periplasmic extracts of cultures containingpBA015 over Talon resin under native conditions. All proteins weredialyzed against phosphate-buffered saline (PBS), reduced to <0.125endotoxin units (EU)/ml lipopolysaccharide by passage through anendotoxin removal column, and quantified by bicinchoninic acid assayprior to the addition of 5% glycerol.

Proteins resolved by SDS-12% PAGE were stained with Coomassie® ortransferred to nitrocellulose membranes. Membranes were blockedovernight with 5% skim milk in PBS plus 0.05% Tween® 20 (PBS-T),incubated with polyclonal anti-CTA (1:2,500) and anti-CTB (1:5,000) oranti-His6 (1:2,500), followed by horseradish peroxidase (HRP)-conjugatedanti-rabbit IgG (1:5,000) and developed with IMMOBILON WESTERN HRPSUBSTRATE commercially available from Millipore, Billerica, Mass.

Example 2

To compare the receptor binding affinity of purified IsdA-CTA₂/B chimerawith native CT, ganglioside GM1 ELISA assays using anti-CTA and anti-CTBantibodies were performed.

GM1 enzyme-linked immunosorbent assays (ELISA) were performed by coatingmicrotiter plates with 0.15 □M GM1 for 15 h at 20° C., blocking with 10%bovine serum albumin, and incubating with IsdA-CTA₂/B or CT for 1 h at37° C. Ganglioside GM1 is found ubiquitously on mammalian cells and actsas the site of binding for both cholera toxin and heat-labile toxin.Plates were washed with PBS-T and incubated with anti-CTA (1:2,000) oranti-CTB (1:5,000) followed by HRP-conjugated anti-rabbit IgG, both for1 h at 37° C. The reaction was developed with o-phenylenediaminedihydrochloride (A₄₅₀).

The ELISA results indicate that the B subunit of IsdA-CTA₂/B has GM1binding affinity similar to that of CT (FIG. 4). Low anti-CTA responsefrom IsdA-CTA₂/B was an expected result from this fusion that containsonly 46 bp of full-length CTA.

Confocal microscopy was used to further confirm receptor binding andinternalization of IsdA-CTA₂/B into epithelial and dendritic cells (DC)in vitro. Immune effector cells, such as dendritic cells, have auniquely high affinity for CT and non-toxigenic CTB. FIGS. 5A-5D showanti-CT FITC-labeled IsdA-CTA₂/B bound to the surface of cells (Veroepithelial cells in FIG. 5A-5B; DC cells in FIG. 5C-5D) at 4° C. andinternalization after 45 min at 37° C., indicating that, at a minimum,the CTB subunit of the chimera were efficiently imported into the cell.These images obtained using polyclonal anti-CT and anti-rabbit-FITC withDAPI suggest that IsdA-CTA₂/B was binding and transporting into Vero andDC2.4 cells. Cells were incubated with IsdA-CTA₂/B for 45 minutes at 4°C. to inhibit, or at 37° C. to promote cellular uptake.

Example 3

The chimeric proteins were tested for their specific humoral response.

BALB/c mice were mock immunized or immunized intranasally withIsdA-CTA₂/B, IsdA plus CTA₂/B mixed, or IsdA on day 0 and boosted on day10 (Table 1 below). FIG. 6 shows systemic antibody response toIsdA-CTA₂/B in vivo. Referring to FIG. 6, sera collected on days 0, 10,14, and 45 were pooled by treatment group at each time point and testedfor recognition of IsdA by IgG ELISA. IsdA-specific serum IgG endpointtiters from mice immunized with IsdA-CTA₂/B were significantly higherthan those of mock-immunized mice on day 10, than those of all controlgroups on day 14, and than those of mice immunized with IsdA alone andmock-immunized mice on day 45. As used herein, “*” denotes statisticalsignificance (P<0.05) between mice immunized with IsdA-CTA₂/B versuscontrols. Nasal, intestinal, and vaginal washes were collected on day45, pooled by treatment group, and tested for recognition of IsdA by IgAELISA.

FIG. 7 shows mucosal antibody response to IsdA-CTA₂/B in vivo. Referringto FIG. 7, the percentage of IsdA-IgA out of total IgA was significantlyhigher in nasal and vaginal washes from mice immunized with IsdA-CTA₂/Bthan from mock-immunized mice, mice immunized with IsdA plus CTA₂/B, ormice immunized with IsdA alone. In addition, intestinal IsdA-IgA wassignificantly higher in IsdA-CTA₂/B-immunized mice than in IsdA- andmock-immunized mice (FIG. 7). Together, these results suggest that IsdAspecific systemic and mucosal humoral immunity can be stimulated afterintranasal vaccination with the IsdA-CTA₂/B chimera.

TABLE 1 Immunization Strategy. Days of sampling Mucosal Dose per Days ofsecretions Antigen/ vaccination intranasal and spleen adjuvant (□ g)n^(b) vaccination Sera (n) IsdA-CTA₂/B 50 8 0, 10 0, 10, 14, 45 14 (2),45 (6) chimera IsdA + 17 + 33^(a) 8 0, 10 0, 10, 14, 45 14 (2), 45 (6)CTA₂/B IsdA 17 8 0, 10 0, 10, 14, 45 14 (2), 45 (6) Mock NA^(c) 8 0, 100, 10, 14, 45 14 (2), 45 (6) ^(a)Concentrations are according toequimolar to equimolar amounts of IsdA ^(b)n, number of mice ^(c)NA, notapplicable

Example 4

Cellular proliferation of IsdA-stimulated splenocytes was assessed usingflow cytometry and a resazurin-based fluorescent dye assay. CFSE-basedflow cytometric results suggest that day 45 splenocytes derived frommice immunized with IsdA-CTA₂/B showed significant proliferation ofIsdA-specific CD3+ T lymphocytes compared with mixed and IsdA controlgroups (FIGS. 8A-8D and 9). Referring to FIGS. 8A-8D, CFSE-labeledsplenocytes were cultured in vitro for 84 h with IsdA and stained withanti-CD3-PE-Cy5. Referring to FIG. 9, percent proliferation ofIsdA-specific CD3+ T lymphocytes from individual mice on day 45 wasdetermined by flow cytometry. Mock samples contained low numbers of CD3+T lymphocytes.

FIG. 10 shows the result of a resazurin assay of splenocytes from days14 and 45 cultured in vitro for 84 h with IsdA. The resazurin assaysrevealed that in vitro stimulation of splenocytes fromIsdA-CTA₂/B-immunized mice induced significant proliferation comparedwith IsdA plus CTA₂/B, IsdA, and mock groups on day 45 (FIG. 10). Withthe low sample size (n=2 per group) on day 14, no significance wasobserved between groups. Error bars are based on n=2 (day 14) or n=6(day 45). Stimulation was observed for the positive control, ConA. Theseresults suggest that intranasal administration of IsdA-CTA₂/B can inducea cellular activation response.

Example 5

The levels of IL-4 and IFN-□□ in supernatants of splenocytes stimulatedwith IsdA in vitro were determined by ELISA. Referring to FIG. 11, IL-4and IFN-□□ levels in culture supernatants from splenocytes, pooled byimmunization group (n=6), were stimulated in vitro for 84 h with IsdAand measured by ELISA. The splenocytes obtained from mice immunized withIsdA-CTA₂/B secreted high levels of IL-4, and these levels weresignificantly higher than levels of all controls (FIG. 11). Although thelevel of IFN-□□ was slightly higher in IsdA-CTA₂/B-immune splenocytes,low levels of IFN-□□, near the detection limit for the assay, were foundin all groups (FIG. 11).

FIG. 12 shows IsdA-specific IgG1 and IgG2a ELISA titrations from day 45sera pooled by immunization group (n=6). Titrations of IgG1 and IgG2arevealed that immunization with IsdA-CTA₂/B drove isotype switchingprimarily to the IgG1 subclass although minute IgG2a levels were alsodetected. These results suggest that immunization with IsdA-CTA₂/Bpromotes a Th2-type immune response.

Example 6

Pooled sera from commonly immunized mice were used to investigate theability of immune serum to functionally block adherence of S. aureus tohuman epithelial cells (HeLa). FIGS. 13A-13B shows the effect of immuneserum on S. aureus adhesion to human epithelial cells in vitro.Referring to FIG. 13A, sera (1:100; day 45) was pooled by immunizationgroup and incubated with MRSA252 (5×10⁷ CFU) for 1 h at 37° C. and thenadded to confluent HeLa cells. After washing and lysis, the number ofinternalized and cell-bound bacteria was enumerated. Preincubation ofthe S. aureus strain used for vaccination (MRSA252) with day 45 serafrom IsdA-CTA₂/B-immunized mice significantly reduced bacterial adhesionto epithelial cells compared to all control groups (FIG. 13A).

FIG. 13B shows the result of similar tests performed with MRSA USA300(5×10⁹ CFU). Referring to FIG. 13B, there was a significant reduction inbacterial adhesion to human epithelial cells after a different strain ofS. aureus (MRSA USA300) was preincubated with day 45 sera from miceimmunized with IsdA-CTA₂/B (FIG. 13B).

These examples suggest that the chimeric proteins of the presentinvention can bind and transport into epithelial and dendritic cells asconsistent with the uptake of CT involving retrograde movement to theperinuclear domain of the Golgi apparatus and endoplasmic reticulum. Itis believed that the ability of the chimeric proteins to bind to GM1 andtrigger internalization leads to the activation of immune effector cellsby the CTB subunit and promotes antigen presentation on MHC molecules.

Moreover, the ELISAs of IsdA-specific responses from the sera and nasal,intestinal, and vaginal fluids of intranasally immunized mice verifiesthat the chimeric proteins can induce antigen-specific systemic andmucosal immunity in mice. As expected, IgG titers were highest on day 14after the boost and began to diminish by day 45.

These results also suggest the characteristic ability of CT to inducesystemic IgG to antigens co-administered with CT at mucosal sites. Thepresence of IsdA-specific IgA in nasal, intestinal, and vaginal fluidsafter intranasal immunization with IsdA-CTA₂/B suggests that IgA blastsmigrated from the nasal-associated lymphoid tissue into distal mucosaleffector sites in the nasal passage and gastrointestinal and genitaltracts. Thus, it is believed that CT and CT derivatives promote more ofa Th2-type response, which is typically characterized by secretion ofIL-4 leading to induction of antibody class switching tonon-complement-activating IgG1. In vitro functional assays of antibodiesrevealed a significant reduction in internalized and cell-bound bacteriaon human epithelial cells after preincubation of IsdA-CTA₂/B immuneserum with the S. aureus isolate used for vaccination, MRSA252.Additionally, antibodies were able to prevent adhesion of MRSA USA300.

IsdA from MRSA252 and MRSA USA300 has 92% amino acid identity with themajority of differences present within the C terminus, which suggeststhat antibodies against IsdA are functional in vitro and may protectagainst multiple serotypes in vivo.

The results also suggest that the humoral and cellular responses inducedby IsdA-CTA₂/B are superior to those stimulated by a mixed preparationof antigen and adjuvant (IsdA plus CTA₂/B). Thus, the structure of theIsdA-CTA₂/B chimera is optimal for the induction of antigen-specifichumoral responses and potentially for presentation on MHC molecules.

Example 7

Milk anti-IsdA IgA titer levels were measured in cows treated with achimeric protein according to one or more embodiments of the presentinvention. Six (1-6 in FIG. 14) clinically healthy Holstein dairy cowswere vaccinated intranasally on day 0 with 300 □g of IsdA-CTA2/B chimera(cows 4-6) or an equivalent concentration of IsdA alone (cows 1-3). Cowswere boosted on day 14 with the same concentration. Milk was collectedon days 0, 14 and 28 and analyzed by IsdA-specific IgA ELISA.

FIG. 14 shows a summary of the titer results. The titer values werecalculated as the reciprocal of the milk dilution that was 0.1 O.D.above background. Referring to FIG. 14, cows 1 (2296), 2 (2299) and 3(2403) represent controls of the experiment while cows 4 (2319), 5(2340) and 6 (2472) were vaccinated (labeled *) with a chimeric protein.Cows 4-6 all displayed increases in the titer on days 14 and 28 ascompared to cows 1-3.

Therefore, the present invention is well adapted to attain the ends andadvantages mentioned as well as those that are inherent therein. Theparticular embodiments disclosed above are illustrative only, as thepresent invention may be modified and practiced in different butequivalent manners apparent to those skilled in the art having thebenefit of the teachings herein. Furthermore, no limitations areintended to the details of construction or design herein shown, otherthan as described in the claims below. It is therefore evident that theparticular illustrative embodiments disclosed above may be altered,combined, or modified and all such variations are considered within thescope and spirit of the present invention. The invention illustrativelydisclosed herein suitably may be practiced in the absence of any elementthat is not specifically disclosed herein and/or any optional elementdisclosed herein. While compositions and methods are described in termsof “comprising,” “containing,” or “including” various components orsteps, the compositions and methods can also “consist essentially of” or“consist of” the various components and steps. All numbers and rangesdisclosed above may vary by some amount. Whenever a numerical range witha lower limit and an upper limit is disclosed, any number and anyincluded range falling within the range is specifically disclosed. Inparticular, every range of values (of the form, “from about a to aboutb,” or, equivalently, “from approximately a to b,” or, equivalently,“from approximately a-b”) disclosed herein is to be understood to setforth every number and range encompassed within the broader range ofvalues. Also, the terms in the claims have their plain, ordinary meaningunless otherwise explicitly and clearly defined by the patentee.Moreover, the indefinite articles “a” or “an,” as used in the claims,are defined herein to mean one or more than one of the element that itintroduces. If there is any conflict in the usages of a word or term inthis specification and one or more patent or other documents that may beincorporated herein by reference, the definitions that are consistentwith this specification should be adopted.

1. An S. aureus specific polypeptide antigen comprising a truncatediron-regulated surface determinant A (IsdA).
 2. The S. aureus specificpolypeptide antigen of claim 1 having a sequence of SEQ ID NO:4 or aprotein with 90% homology thereto.
 3. The protein of claim 1, whereinsaid (IsdA) protein comprises the amino acid sequence as set forth inSEQ ID NO: 5 or SEQ ID NO:
 6. 4. A chimeric protein comprising theantigen of claim 1 and an adjuvant protein.
 5. The chimeric protein ofclaim 4 comprising SEQ ID NO:4 or a protein with 90% homology thereto.6. The chimeric protein of claim 5 wherein said adjuvant is selectedform the group consisting of: a portion of cholera toxin, a portion ofheat labile toxin, or a portion of shiga toxin.
 7. The chimeric proteinof claim 6 wherein said adjuvant is cholera toxin subunit A or B, heatlabile toxin subunit B, or Shiga toxin subunit B.
 8. The chimericprotein of claim 7 wherein said adjuvant is cholera toxin adjuvantprotein is CTA₂ or CTB.
 9. The chimeric protein of claim 5 wherein thechimeric protein is assembled from a first polypeptide and a secondpolypeptide that are non-covalently linked.
 10. The chimeric protein ofclaim 5 wherein the chimeric protein is a fusion protein.
 11. Thechimeric protein of claim 8 comprising a sequence of SEQ ID NO: 2, 3, 5,or 6, or a sequence with 90% homology thereto.
 12. An immunogeniccomposition comprising the chimeric protein of claim 1 and a carrier.13. The immunogenic composition of claim 12 further comprising anadjuvant protein.
 14. The immunogenic composition of claim 13 whereinsaid adjuvant is selected form the group consisting of: a portion ofcholera toxin, a portion of heat labile toxin, or a portion of shigatoxin.
 15. The immunogenic composition of claim 14 wherein said adjuvantis cholera toxin subunit A or B, heat labile toxin subunit B, or Shigatoxin subunit B.
 16. The immunogenic composition of claim 15 whereinsaid adjuvant is cholera toxin adjuvant protein is CTA₂ or CTB.
 17. Theimmunogenic composition of claim 16 wherein said cholera toxin adjuvanthas a sequence of SEQ ID NO: 2 or 3 or a sequence with 90% homologythereto.
 18. The immunogenic composition of claim 13 wherein thechimeric protein is assembled from a first polypeptide and a secondpolypeptide that are non-covalently linked.
 19. The immunogeniccomposition of claim 13 wherein the chimeric protein is a fusionprotein.
 20. The immunogenic composition of claim 13 having a sequenceof SEQ ID NO: 5 or SEQ H) NO: 6, or a sequence with 90% homologythereto.